{"transactions":[{"id":758900,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-29T23:07:42.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":120000,"derivative":{"exercise_price":0.7989,"exercise_date":"2027-05-28","expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193125-26-249052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000119312526249052/ownership.xml","form_type":"4"}},{"id":791918,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."}],"balance_after":0,"derivative":{"exercise_price":37.18,"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":791917,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."}],"balance_after":0,"derivative":{"exercise_price":7.31,"underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":791916,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":955534,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":955534},"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":791915,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"price":53,"value":7950000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") award then outstanding, whether or not vested, was cancelled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Merger Consideration and the total number of Shares subject to such RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":791914,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"other","planned":false,"acquired":false,"shares":8319,"price":53,"value":440907.0,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":791913,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-05T21:00:12.000Z","date":"2026-05-05","kind":"other","planned":false,"acquired":false,"shares":146614,"price":53,"value":7770542.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 7,638 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan since the reporting person's Form 4 filed on March 17, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 24, 2026, Terns Pharmaceuticals, Inc. (the \"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Merck Sharp & Dohme LLC (\"Merck\") and Thailand Merger Sub, Inc. (the \"Purchaser\"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the \"Shares\"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the \"Merger Consideration\"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001872564-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000010/primarydocument.xml","form_type":"4"}},{"id":838348,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-17T22:10:28.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":false,"shares":14583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":955534,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14583},"source":{"system":"sec-edgar","filing":"0001872564-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000008/primarydocument.xml","form_type":"4"}},{"id":838347,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:10:28.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":2770,"price":47.3024,"value":131027.648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sale price represents the weighted average sale price of the shares sold ranging from $47.01 to $47.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":288976,"source":{"system":"sec-edgar","filing":"0001872564-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000008/primarydocument.xml","form_type":"4"}},{"id":838346,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:10:28.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":11813,"price":46.5657,"value":550080.6141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This sale price represents the weighted average sale price of the shares sold ranging from $46.01 to $47.005 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":291746,"source":{"system":"sec-edgar","filing":"0001872564-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000008/primarydocument.xml","form_type":"4"}},{"id":838345,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:10:28.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":true,"shares":14583,"price":4.64,"value":67665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."}],"balance_after":303559,"source":{"system":"sec-edgar","filing":"0001872564-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000008/primarydocument.xml","form_type":"4"}},{"id":897208,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T00:01:31.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":false,"shares":14583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":970117,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14583},"source":{"system":"sec-edgar","filing":"0001872564-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000006/primarydocument.xml","form_type":"4"}},{"id":897207,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-19T00:01:31.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":4083,"price":39.7995,"value":162501.3585,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This sale price represents the weighted average sale price of the shares sold ranging from $39.54 to $40.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":288976,"source":{"system":"sec-edgar","filing":"0001872564-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000006/primarydocument.xml","form_type":"4"}},{"id":897206,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-19T00:01:31.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":8159,"price":39.216,"value":319963.344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sale price represents the weighted average sale price of the shares sold ranging from $38.54 to $39.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":293059,"source":{"system":"sec-edgar","filing":"0001872564-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000006/primarydocument.xml","form_type":"4"}},{"id":897205,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-19T00:01:31.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2341,"price":38.0668,"value":89114.3788,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This sale price represents the weighted average sale price of the shares sold ranging from $37.54 to $38.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":301218,"source":{"system":"sec-edgar","filing":"0001872564-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000006/primarydocument.xml","form_type":"4"}},{"id":897204,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-19T00:01:31.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":true,"shares":14583,"price":4.64,"value":67665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."}],"balance_after":303559,"source":{"system":"sec-edgar","filing":"0001872564-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000006/primarydocument.xml","form_type":"4"}},{"id":937355,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":false,"shares":14583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":984700,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14583},"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937354,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":false,"shares":27083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":999283,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":27083},"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937353,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":false,"shares":27083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":1026366,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":27083},"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937352,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-14","kind":"grant","planned":true,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":300000,"derivative":{"exercise_price":37.18,"expiration_date":"2036-01-13","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937351,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":7521,"price":37.5256,"value":282230.0376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This sale price represents the weighted average sale price of the shares sold ranging from $37.45 to $37.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote"}],"balance_after":288976,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937350,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":61228,"price":37.0153,"value":2266372.7884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sale price represents the weighted average sale price of the shares sold ranging from $36.45 to $37.445 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote"}],"balance_after":296497,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937349,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":true,"shares":14583,"price":4.64,"value":67665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."}],"balance_after":357725,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937348,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":true,"shares":27083,"price":4.64,"value":125665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."}],"balance_after":343142,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937347,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-15","kind":"exercise","planned":true,"acquired":true,"shares":27083,"price":4.64,"value":125665.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025."}],"balance_after":316059,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":937346,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-16T22:22:28.000Z","date":"2026-01-14","kind":"grant","planned":true,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the \"Vesting Commencement Date\"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":288976,"source":{"system":"sec-edgar","filing":"0001872564-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000004/primarydocument.xml","form_type":"4"}},{"id":947115,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-07T01:26:57.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive, upon vesting, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock unit award was granted on March 1, 2024. The restricted stock unit award was subject to vesting as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $20.00 per share. The performance criteria for the specified milestones were determined to have been achieved by the Compensation Committee as to 100% of the underlying shares, and the delivery and release of the underlying shares occurred on January 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock unit award was granted on March 1, 2024. The restricted stock unit award was subject to vesting as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equaled or exceeded $20.00 per share. The performance criteria for the specified milestones were determined to have been achieved by the Compensation Committee as to 100% of the underlying shares, and the delivery and release of the underlying shares occurred on January 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001872564-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000002/primarydocument.xml","form_type":"4"}},{"id":947114,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:26:57.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":21551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vested on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":1053449,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":21551},"source":{"system":"sec-edgar","filing":"0001872564-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000002/primarydocument.xml","form_type":"4"}},{"id":947113,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:26:57.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":71339,"price":38.103,"value":2718229.917,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This sale price represents the weighted average sale price of the shares sold ranging from $37.43 to $39.595 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":138976,"source":{"system":"sec-edgar","filing":"0001872564-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000002/primarydocument.xml","form_type":"4"}},{"id":947112,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:26:57.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive, upon vesting, one share of common stock."}],"balance_after":210315,"source":{"system":"sec-edgar","filing":"0001872564-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000002/primarydocument.xml","form_type":"4"}},{"id":947111,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:26:57.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":21551,"price":4.64,"value":99996.64,"ownership":{"direct":true},"balance_after":60315,"source":{"system":"sec-edgar","filing":"0001872564-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000187256426000002/primarydocument.xml","form_type":"4"}},{"id":1101777,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-25T22:08:58.000Z","date":"2025-06-25","kind":"purchase","planned":false,"acquired":true,"shares":23314,"price":3.8702,"value":90229.8428,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,160 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2025."}],"balance_after":47083,"source":{"system":"sec-edgar","filing":"0001562180-25-005077","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218025005077/primarydocument.xml","form_type":"4"}},{"id":1129385,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-05-30T22:52:57.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":107400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":107400,"derivative":{"exercise_price":0.4444,"exercise_date":"2026-05-29","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":107400},"source":{"system":"sec-edgar","filing":"0000950170-25-079948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000095017025079948/ownership.xml","form_type":"4"}},{"id":1287558,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T00:25:48.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":1075000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":1075000,"derivative":{"exercise_price":4.64,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":1075000},"source":{"system":"sec-edgar","filing":"0001562180-25-000851","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218025000851/primarydocument.xml","form_type":"4"}},{"id":1287557,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-04T00:25:48.000Z","date":"2024-11-30","kind":"purchase","planned":false,"acquired":true,"shares":510,"price":5.11,"value":2606.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes an additional 510 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024 that was not previously reported on the reporting person's Form 4 filed on December 9, 2024 due to an administrative error."}],"balance_after":19609,"source":{"system":"sec-edgar","filing":"0001562180-25-000851","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218025000851/primarydocument.xml","form_type":"4"}},{"id":1339171,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-09T23:04:56.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":15450,"price":7.15,"value":110467.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,649 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan (\"ESPP\") on November 30, 2024."}],"balance_after":19099,"source":{"system":"sec-edgar","filing":"0001562180-24-008254","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218024008254/primarydocument.xml","form_type":"4"}},{"id":1383556,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-10-22T00:35:49.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":34000,"derivative":{"exercise_price":2.04,"exercise_date":"2025-05-31","expiration_date":"2034-10-17","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0000950170-24-116058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000095017024116058/ownership.xml","form_type":"4"}},{"id":1597448,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2024-03-05T23:01:54.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from March 1, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":1250000,"derivative":{"exercise_price":7.31,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001562180-24-002316","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218024002316/primarydocument.xml","form_type":"4"}},{"id":1597447,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-03-05T23:01:54.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock unit award has a four-year term and vests based on the achievement of milestones stock prices with respect to the Issuer's common stock, subject to the Reporting Person's continued employment through the applicable vesting milestones. The restricted stock unit award vests as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $20.00 per share; provided that vesting shall not be deemed to occur earlier than the first anniversary of the Reporting Person's first day of employment and that vesting must be achieved on or before the fourth anniversary of the first day of employment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock unit award has a four-year term and vests based on the achievement of milestones stock prices with respect to the Issuer's common stock, subject to the Reporting Person's continued employment through the applicable vesting milestones. The restricted stock unit award vests as to 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $15.00 per share and as to the remaining 50% of the shares underlying the award if the average closing price of the Issuer's common stock over 30 consecutive trading days equals or exceeds $20.00 per share; provided that vesting shall not be deemed to occur earlier than the first anniversary of the Reporting Person's first day of employment and that vesting must be achieved on or before the fourth anniversary of the first day of employment."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-24-002316","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000156218024002316/primarydocument.xml","form_type":"4"}},{"id":1859105,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-06-13T00:09:13.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":14766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant  or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":14766,"derivative":{"exercise_price":7.12,"exercise_date":"2024-06-09","expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":14766},"source":{"system":"sec-edgar","filing":"0001209191-23-036502","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000120919123036502/doc4.xml","form_type":"4"}},{"id":2072912,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2023-01-03T21:36:27.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":17156,"price":1.53,"value":26248.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan."}],"balance_after":73288,"source":{"system":"sec-edgar","filing":"0001235802-23-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000123580223000003/primary_doc.xml","form_type":"4"}},{"id":2093492,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-12-07T23:20:23.000Z","date":"2022-12-05","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/36th of the total number of shares subject to the option on the one (1) month anniversary of the Transaction Date and 1/36th of the total number of shares subject to the option on each monthly anniversary thereafter, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":2.42,"exercise_date":"2023-01-05","expiration_date":"2032-12-04","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-060234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000120919122060234/doc4.xml","form_type":"4"}},{"id":2247811,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-02T20:58:21.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":13222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":13222,"derivative":{"exercise_price":2.45,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":13222},"source":{"system":"sec-edgar","filing":"0001235802-22-000074","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000123580222000074/primary_doc.xml","form_type":"4"}},{"id":2454577,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2022-01-03T21:39:02.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":11182,"price":3.58,"value":40031.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,182 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan."}],"balance_after":56132,"source":{"system":"sec-edgar","filing":"0001235802-22-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000123580222000004/primary_doc.xml","form_type":"4"}},{"id":2600634,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2021-08-17T20:11:42.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":44950,"price":3.15,"value":141592.5,"ownership":{"direct":true},"balance_after":44950,"source":{"system":"sec-edgar","filing":"0001235802-21-000101","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000123580221000101/primary_doc.xml","form_type":"4"}},{"id":2632256,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":43198,"kind":"person","name":"Burroughs Amy L.","position":1,"cik":"0001872564","reported_name":"Burroughs Amy L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-16T20:35:27.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":18786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in twelve nearly equal quarterly installments over three years."}],"balance_after":18786,"derivative":{"exercise_price":3.64,"expiration_date":"2031-07-14","underlying":"Common Shares","underlying_shares":18786},"source":{"system":"sec-edgar","filing":"0001235802-21-000079","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872564/000123580221000079/primary_doc.xml","form_type":"4"}}]}